Sunny Pharmtech has signed a 5-year contract with a British pharmaceutical company for Carboprost injections, with plans to submit the application in 2024 Q4 and obtain UK drug approval in 2025 Q4. Carboprost is used for the treatment of therapeutic abortion and postpartum hemorrhage. According to IQVIA database, the sales of this drug in the UK reached 10 million dollars in the past year.